Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSG | P08311 | 3/20 | 0.71 |
| ▸ | CMA1 | P23946 | 3/20 | 0.71 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.54 |
| ▸ | PDPK1 | O15530 | 3/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | PTGDR2 | Q9Y5Y4 | 7/20 | 0.52 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | AR | P10275 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5622038 | 0.91 | CMA1 (0.59) | CTSGCMA1L3MBTL1PDPK1KMT2A | |
| SCHEMBL5621097 | 0.90 | CTSG (0.60) | CTSGCMA1L3MBTL1PDPK1KMT2A | |
| SCHEMBL5621193 | 0.90 | CTSG (0.60) | CTSGCMA1L3MBTL1PTGDR2HCRTR1 | |
| SCHEMBL5266755 | 0.89 | PTGDR2 (0.64) | CTSGCMA1L3MBTL1PDPK1KMT2A | |
| SCHEMBL5620685 | 0.88 | CMA1 (0.57) | CTSGCMA1L3MBTL1PDPK1KMT2A | |
| SCHEMBL5622172 | 0.88 | CMA1 (0.57) | CTSGCMA1L3MBTL1PDPK1KMT2A | |
| SCHEMBL4455217 | 0.87 | CTSG (0.75) | CTSGCMA1L3MBTL1PDPK1KMT2A | |
| SCHEMBL14577955 | 0.87 | CMA1 (0.54) | CTSGCMA1L3MBTL1PDPK1KMT2A | |
| SCHEMBL5405060 | 0.86 | CMA1 (0.60) | CTSGCMA1L3MBTL1PDPK1KMT2A | |
| SCHEMBL5622412 | 0.83 | CTSG (0.57) | CTSGCMA1L3MBTL1PDPK1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070032466-A1 | Drug containing chymase inhibitor as the active ingredient | TEIJIN PHARMA LIMITED (JP) | 2007-02-08 | — | — | US | claimed |
| EP-1666067-A1 | DRUG CONTAINING CHYMASE INHIBITOR AS THE ACTIVE INGREDIENT | Teijin Pharma Limited (JP) | 2006-06-07 | — | — | EP | claimed |
| EP-1249450-B1 | BENZIMIDAZOLE DERIVATIVES AS HUMAN CHYMASE INHIBITORS | TEIJIN PHARMA LTD (JP) | 2007-10-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032466-A1 | Drug containing chymase inhibitor as the active ingredient | REN, SERPINB1, CMA1 | CTSG 40/4885CMA1 3/4885L3MBTL1 4241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.